Strides, TLC partner to launch black fungus drug in India
PTI
Updated May 27, 2021, 3:13 pm IST
AmphoTLC will be imported from Taiwan by Stelis Biopharma Pvt Ltd
The Central Drugs Standard Control Organization (CDSCO) has approved TLC's new drug application. (Photo: PTI)
New Delhi: Strides Pharma Science and Taiwan-based specialty pharmaceutical firm TLC have partnered to launch Liposomal Amphotericin B, a drug used in the treatment of mucormycosis (black fungus), in India.
The Central Drugs Standard Control Organization (CDSCO) has approved TLC's new drug application (NDA) of Amphotericin B Liposome for Injection 50mg in India for immediate importation per approved usage and indication, Strides and TLC said in a joint statement on Thursday.